AllCells - San Francisco Bay Area

AllCells - San Francisco Bay Area

Alameda, California

Since its inception in 1998, AllCells has been a forward-thinking company with a fervent focus on providing the highest quality cells for biomedical researchers. Founded by Dr. Jay Tong, who, at that time, was a research scientist at Novartis-Systemix, AllCells was the first to provide a comprehensive portfolio of commercially available blood and bone marrow-derived primary cells including mobilized LeukoPak products to the market. This pioneering spirit led to the creation of a robust donor management system, optimized protocols for isolating human cells and the collection of human tissues in accordance with GMP standards, and a state-of-the-art quality management system.

Dr. Jay Tong, CEO of AllCells
Jay Tong, MD, CEO of AllCells

Consider AllCells part of your research team – helping you achieve your research goals with the flexibility to meet specific, customized needs. Our expertise in research grade and GMP-compliant products are leveraged by biomedical researchers in cell and gene therapy, immuno-oncology, stem cell therapy, and contract development manufacturing organizations. With the largest repository of healthy, reliable and recallable donors, even the most unique customer needs are possible. Located in the San Francisco Bay Area and the Boston Metropolitan area, AllCells bicoastal collection facilities streamline tissue collection and cell procurement, allowing the delivery of cells in as little as 3 days.

At its core, AllCells is a customer-focused company committed to providing high-quality cellular products to its customers. Continuous improvement initiatives enable AllCells to meet customer’s needs as they evolve. Whether it is developing new products, optimizing existing products, or improving the customer experience through its easy-to-use, Amazon-like webstore, innovative ideas backed by a dedicated team ensures that the company’s guiding principle, to put its customers and their research first, is met. AllCells – Quality Cells for Quality Science.

Mission


At AllCells, our mission is to support researchers in making groundbreaking discoveries in life science and improve human health. Our role is delivering the highest quality hematology and immunology cell-based products and bio services consistently, reliably, and affordably.

Our Vision is to:

  • Be the industry preferred biotechnology company, globally.
  • Adapt to market trends to meet our customers’ special needs.
  • Advance the industry by inspiring researchers through our drive to innovate.
  • Deliver quality products and services for life science research and clinical grade applications.
  • Revolutionize the process of ordering cells through a customer-centric approach featured on AllCells’ Webstore.

AllCells Advantage


For the past 22 years, AllCells has been the leading provider of high-quality human primary blood and marrow-based cells. Through experience and scientific expertise, AllCells maintains the best-in-class products and services with optimized protocols that ensure research and clinical grade products are delivered on time to pharmaceutical, biotechnology, medical device, healthcare, and academic institutions around the world.

By sourcing through our on-site, IRB-approved, state-of-the-art donor and management facilities, AllCells offers the fastest delivery time in the industry for custom orders. After collecting cells and whole tissue from a large repository of recallable, healthy donors, AllCells immediately processes fresh tissue in our adjacent labs, producing purified cell types with unparalleled quality and consistency.

By consistently delivering high-viability, high-purity subtypes, and guaranteeing an accurate cell count, AllCells has earned a reputation for high-quality cells with the ability to customize our product to meet even the most unique requirements. AllCells – Quality Cells for Quality Science

Our Promise


At AllCells, we understand that high-quality starting materials are essential to better patient outcomes. We are committed to the endless pursuit of our passion for innovation and customer engagement.

The Right Cells

The Right Cells

 

Quality and viability you can trust

  • Comprehensive validation protocols.
  • Unsurpassed donor screening protocols.
  • Multiple cell types for a wide variety of research applications.
  • Customized services to meet project requirements.

 

At the Right Time

At the Right Time

 

Special orders delivered in three days

  • On-site blood and marrow collection facilities ensure supply chain control.
  • Delivered when you need them.
  • Worldwide service – now delivered faster.
  • Easy ordering with real-time chat & inventory checks.

 

AllCells Capabilities

AllCells Capabilities

 

Experienced provider

  • Donor recruitment and retention.
  • Optimized cell isolation protocols.
  • Quality management system.

 

History


Founded in 1998, AllCells is a biotechnology company dedicated to providing global researchers and biomanufacturing organizations with a dependable supply of biologically-relevant, high-quality primary cells that enable drug discovery, development, and manufacturing of cell therapies. Leveraging its expertise in hematology and immunology cell isolations, combined with on-site whole blood and bone marrow tissue collection operations, AllCells maintains direct access to a large repository of diverse donor profiles that can be further screened and qualified for biomedical applications. Utilizing its contiguous cell processing facilities, freshly collected tissue is immediately processed into purified cell types with unparalleled quality consistency. This optimal work flow provides for the highest viability, purity, and cell count available. Fresh or frozen cells are shipped worldwide, or fresh cells can be immediately utilized in fee-for-service cell-based assays – delivering cell culture results/data to meet client project timelines.

1998 – 2003
  • AllCells Founded in Berkeley, California by Jay Tong, M.D.
  • Published first catalog offering a wide range of products and bioservices.
  • Delivered directly to local, domestic and global customers.
2003 – 2008
  • Established IRB-approved, state-of-the-art donor facilities to collect cells and whole tissue from a large repository of recallable donors which enables custom orders to be fulfilled in the shortest time in the industry.
  • Employed cutting-edge processing tools, such as AutoMACS and CliniMACS.
  • Further diversified product portfolio by adding numerous CD34+ isolated cell products and fresh cord blood.
2008 – 2013
  • Ranked among the fastest growing privately owned United States companies by Inc. 500.
  • Achieved the “Fast 50 Award” award from by the United States Pan Asian American Chamber of Commerce
  • Relocated to AllCells existing Headquarters in Alameda, California.
2013 – 2020
  • Began delivering GMP Clinical Grade products to the biomedical research market.
  • Grand Opening of AllCells Boston offices.
  • Integrated enterprise systems solutions Oracle Netsuite.
  • Lonza partnership.
  • Two Bi-Coastal Successful Collection Sites.

Management Team

JAY TONG, MD

Founder and CEO

Jay Tong founded AllCells, LLC in 1998 and served as the company’s President and CEO until 2018 when he became Chairman. While working as a Research Scientist at Novartis-Systemix (Palo Alto, CA) in the 1990s, Dr. Tong recognized an industry need for a readily-available, commercial source of hematologic tissue such as bone marrow, cord blood, and peripheral blood, and purified hematology and immunology primary cell types needed to support scientific research, drug discovery, and development. Jay earned his M.D. from Suzhou Medical College in China, and completed graduate studies in Hematology at Henan University at Zheng Zhou. He later completed his Hematology Fellowship at the prestigious Genoa Medical School in Italy, a world leader in bone marrow transplantation. Additional post-doctoral training took Dr. Tong to Dr. Ronald Hoffman’s Lab at Indiana University Medical School at Indianapolis. Dr. Tong has published over thirty (30) peer-reviewed papers relating to stem cell purification, ex vivo expansion, gene transduction, and hematopoietic stem cell transplantation.

Danny Zheng, MBA

President

Danny Zheng had held CEO and CFO positions in several public companies listed at the NYSE, American Stock Exchange (merged into NYSE), and OTC Markets. Danny has extensive experience in managing complex global entities, business development and transformation, finance, and SEC compliance in the information technology, consumer product, and hedge fund industries. Most recently, Danny was the CEO of GlassBridge Enterprises, Inc. a public traded investment advisor focusing on technology-driven quantitative funds.

In Danny’s early career, he worked in the computer motherboard industry and served as general manager of the Latin American region for a major brand. During his tenure, he established distribution channels throughout the Latin American region and pioneered a motherboard manufacturing facility in the Brazil free trade zone – Manaus, Amazonas.

Danny holds an MBA degree from the Wharton School at the University of Pennsylvania and a Bachelor of Arts in Accounting from Nankai University (China). Danny is also a Certified Public Accountant.

TED PARENTI

Chief Financial Officer

Ted Parenti, CFO, joined AllCells in May 2016. Ted brings extensive experience in accounting, capital investment, and budgeting, as well as forecast/analysis using ERP systems to AllCells. Ted has primary responsibility for leading the company’s accounting control, financial reporting, and forecasting processes.

Prior to joining AllCells, Ted served as the Industrial Controller for Bio-Rad Laboratories, Inc., where he was responsible for financial control covering multiple operational sites within Bio-Rad’s life science division. Ted has held several financial management positions including Cost Accounting Manager at Peet’s Coffee and Tea, Cost Manager with The Clorox Company, and Regional Finance Manager with General Mills Operations, Inc.

VALERIE GOODWIN-ADAMS, MBA

Chief Revenue Officer

Valerie Goodwin-Adams, CRO, joined AllCells in 2018 to develop and lead AllCells’ marketing, sales, and customer success strategies. Valerie brings over 25 years of extensive top-line revenue-generating experience in FDA-regulated, biopharma, and medical device industries to AllCells. Prior to joining AllCells, Valerie served as the Sr. Director of Global Marketing and Development at Abaxis Global Diagnostics (acquired by Zoetis for 2.2B) for 13 years, where she built a Global Diagnostic Direct Sales, Product Management and Marketing Teams. Valerie has held product marketing and sales development positions of increasing responsibility at Agilent Technologies, Dako Cytomation, and Cadence Design Systems.

Valerie holds a B.A. in Communications from San Jose State University, CA, and an MBA from Brigham Young University (BYU) Marriott School of Business, UT. In addition, Valerie holds a Digital Marketing Certificate from Cornell University and an Advanced Global Leadership Certificate from Lucas Graduate School of Business.

SHEILA SMITH, RN, BSN, HP (ASCP)

Senior Director | Clinical Operations

Sheila Smith, Senior Director of Clinical Operations, joined AllCells in July 2014. Sheila brings over 30 years of clinical experience with specialization in therapeutic and donor apheresis, immunology, and clinical research to AllCells. Additional experience includes fiscal management, state and federal regulatory compliance, development of standard operating procedures, and quality programs.

Prior to joining AllCells, Sheila served as the Apheresis Regional Manager at Fresenius Medical Care, where she was responsible for the operations and clinical oversight of a Northern California mobile apheresis program serving over 65 hospitals and healthcare organizations. Sheila holds a B.S. in Nursing (Grand Valley State College, Allendale, MI) and a Hemapheresis Practitioner Certification through the American Society for Clinical Pathology.

CHERYL COVERT, MBA

Director | Quality Assurance and Quality Control

Cheryl Covert, Director of Quality Assurance & Quality Control, joined AllCells in 2017 to ensure AllCells’ Research and Clinical Operations meet applicable domestic and international regulatory requirements. Cheryl brings more than 25 years of extensive quality management and compliance experience in the FDA-regulated biopharmaceutical and medical device industries. Prior to joining AllCells, Cheryl held several positions of increasing responsibility in quality and manufacturing at Chiron Corporation (acquired by Novartis) before heading the Quality Assurance program for the Clinical Systems Division at Bio-Rad Laboratories.

Cheryl holds a B.S. in Microbiology from San Jose State University, CA, and an MBA from St. Mary’s College, CA.

Have a question? Let’s chat.